Loading
Prime Medicine, Inc. Stock: price and insider trades · United States
US·Mcap US$723.7M
No insider purchase over the last 90 days. The latest was filed 05 Aug 2025.
Prime Medicine, Inc.: what insiders have been doing
This page follows insider dealings at Prime Medicine, Inc. as filed with SEC (Form 4). Nothing new has been filed by managers of Prime Medicine, Inc. in twelve months, the latest record being from 5 August 2025.
Our records for Prime Medicine, Inc. go back to 2022, with 10 purchases and 7 sales on the open market in total.
Elsewhere in the same market, our signals recently picked up insider purchases at GameStop Corp. and Heico Corp. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
43
Thresholds
n/a
Buy Volume
€32M
10 ops. · all time
Sell Volume
€4M
7 ops. · all time
Who traded when
BuySaleDavid R. Liu4 buys
Allan Reine1 buy
Ann L. Lee1 buy
ARCH Venture Partners X, LLC1 buy
ARCH Venture Partners XII, LLC1 buy
GV 2021 GP, L.L.C.1 buy
+2 other insiders
Since the insiders bought
- -27.5%Entry US$4.07 · Close at T+365 US$2.95
- -37.6%Entry US$4.50 · Close at T+365 US$2.81
- +26.1%Entry US$3.07 · Close at T+365 US$3.87
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Prime Medicine, Inc. Strong Buy (bullish), based on 11 analysts. Average price target: US$7.11.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$3.99
Analyst consensus
11 analystsStrong buy
US$4.25Target US$7.11(+78%)US$11.00
Income statement
RevenueUS$4.6M
EBITDA-US$201M-4340% margin
Net income-US$201.1M-4342.4% margin
Valuation
PER (forward)-4.5x
P/Book17.7x
Beta2.38
Balance sheet & cash
Market capUS$723.7M
Total debtUS$116.4M
Free Cash Flow-US$167.1M
Debt / Equity283%
Profitability & ownership
ROE-373.3%
ROA-46.5%
% insiders20.3%
% institutions71.0%
Last declaration on 5 August 2025
Declarations43 total
1,500,000 shares@ US$3.30100.0% of flowCommon StockSEC:0001415889-25-021025:0
Canonical exit: 30 Oct 2025 (T+90)
3,030,300 shares@ US$3.3032.0% of flowCommon StockSEC:0001062993-25-013462:0
Canonical exit: 30 Oct 2025 (T+90)
▲
Same trade as the filing by Robert Nelsen, counted once · View ↗
3,030,300 shares@ US$3.3032.0% of flowCommon StockSEC:0001062993-25-013461:0
Canonical exit: 30 Oct 2025 (T+90)
▲
Same trade as the filing by Robert Nelsen, counted once · View ↗
3,030,300 shares@ US$3.3032.0% of flowCommon StockSEC:0001062993-25-013460:0
Canonical exit: 30 Oct 2025 (T+90)
21,000 shares@ US$2.515732.0% of flowCommon StockSEC:0001628280-25-033754:0
Canonical exit: 28 Sept 2025 (T+90)
21,000 shares@ US$2.16227.9% of flowCommon StockSEC:0001628280-25-032626:0
Canonical exit: 21 Sept 2025 (T+90)
21,000 shares@ US$1.485519.3% of flowCommon StockSEC:0001628280-25-031637:0
Canonical exit: 14 Sept 2025 (T+90)
21,000 shares@ US$1.599520.8% of flowCommon StockSEC:0001628280-25-031045:0
Canonical exit: 9 Sept 2025 (T+90)
125,000 shares@ US$1.1772100.0% of flowCommon StockSEC:0001894562-25-000026:0
Canonical exit: 19 Aug 2025 (T+90)
20,000 shares@ US$1.1895100.0% of flowCommon StockSEC:0001894562-25-000030:0
Canonical exit: 18 Aug 2025 (T+90)
100,000 shares@ US$1.13100.0% of flowCommon StockSEC:0001894562-25-000028:0
Canonical exit: 19 Aug 2025 (T+90)
226,925 shares0Common StockSEC:0001894562-24-000043:0
250,000 shares0Common StockSEC:0001894562-24-000026:0
▲
Same trade as the filing by ARCH Venture Partners XII, LLC, counted once · View ↗
3,200,000 shares@ US$6.2568.0% of flowCommon StockSEC:0001062993-24-003740:0
Canonical exit: 15 May 2024 (T+90)
▲
Same trade as the filing by ARCH Venture Partners XII, LLC, counted once · View ↗
3,200,000 shares@ US$6.2568.0% of flowCommon StockSEC:0001062993-24-003738:0
Canonical exit: 15 May 2024 (T+90)
3,200,000 shares@ US$6.2568.0% of flowCommon StockSEC:0001062993-24-003739:0
Canonical exit: 15 May 2024 (T+90)
7,500 shares0Common StockSEC:0001894562-23-000034:0
1,000,000 shares0Common StockSEC:0001894562-23-000032:0
1,000,000 shares0Common StockSEC:0001894562-23-000030:0
37,405 shares0Common StockSEC:0001209191-23-039122:0
66,659 shares0Common StockSEC:0001209191-23-038363:0
28,100 shares0Common StockSEC:0001209191-23-037334:0
15,672 shares@ US$14.48345.4% of flowCommon StockSEC:0001209191-23-036666:1
16,031 shares@ US$14.98045.7% of flowCommon StockSEC:0001209191-23-036666:3
15,672 shares0Common StockSEC:0001209191-23-036666:0
25 of 43 declarations
About Prime Medicine, Inc.
Prime Medicine, Inc. is a biotechnology company focused on developing gene therapies to treat genetic diseases. It employs advanced technology to design innovative treatments.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
